Esperion Expects Speedy Regulatory Path For Bempedoic Acid/Zetia Combo
Company plans to file the fixed-dose combination through FDA's 505(b)2 pathway, alongside a filing for bempedoic acid itself.
Company plans to file the fixed-dose combination through FDA's 505(b)2 pathway, alongside a filing for bempedoic acid itself.